FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound by the formula I, or to a pharmaceutically acceptable salt, or enantiomer, or tautomer thereof; wherein X1 and X2 are independently selected from a bond or CRaRb; X3 constitutes S; X4 is selected from N or CRc, and Ra, Rb, and Rc are independently selected from H, an unsubstituted C1-6alkyl, or an unsubstituted C1-6alkoxyl; R1, R2, R3, R4, and R7 are independently selected from H, an unsubstituted C1-6alkyl, or an unsubstituted C1-6alkoxyl; ring A is selected from a substituted or unsubstituted C5-6aryl, or a substituted or unsubstituted 5-6-membered heteroaryl, wherein the heteroaryl contains 1 or 2 heteroatoms selected from the following atoms: N or S; ring C is selected from a substituted or non-substituted 9-membered bicyclic heterocyclyl, a substituted or unsubstituted C5-6 monocyclic aryl, a substituted or unsubstituted 5-6-membered monocyclic heteroaryl, or a substituted or unsubstituted 9-membered bicyclic heteroaryl, wherein the heterocyclyl or heteroaryl contains 1-4 heteroatoms selected from the following atoms: N, O, or S; R5 and R6 are independently selected from H, -OH, a halogen, a cyano, a substituted or unsubstituted amino, a substituted or unsubstituted C1-6alkyl, or an unsubstituted C1-6alkoxyl; n constitutes any integer from 0 to 3; and wherein the term “substituted” relates to one or more hydrogen atoms in the group, substituted with a substitute selected from: halogen, -OH, -NH2, -NH(unsubstituted C1-6alkyl), -CN, a halogenated C1-8alkyl, an unsubstituted C1-8alkoxyl. Also proposed is a method for producing the compound by the formula I.
EFFECT: compound by the formula I has a higher inhibitory activity against SHP2 and, thus, can be applied to prevent or treat an SHP2-associated disease.
21 cl, 4 tbl, 23 ex
Title | Year | Author | Number |
---|---|---|---|
DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
PROTEIN TYROSIN PHOSPHATASE INHIBITORS | 2020 |
|
RU2799449C2 |
SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2687093C1 |
2-AMINOPYRASINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | 2013 |
|
RU2642777C2 |
CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
SPIROINDOLIN COMPOUNDS FOR TREATING AND PREVENTING THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | 2015 |
|
RU2734248C2 |
FURIN INHIBITORS | 2019 |
|
RU2799824C2 |
Authors
Dates
2022-10-05—Published
2019-11-05—Filed